Rheumatic heart disease remains a significant public health challenge in developing nations, often affecting children who appear healthy. For many, Rheumatic Heart Disease screening is the only way to detect valvular damage before clinical symptoms like heart failure manifest. A cross-sectional study in Ethiopia recently highlighted a stark reality, revealing that many cases go unnoticed in underserved communities. These findings are particularly relevant for clinicians in India, where the burden of subclinical valvular disease continues to be underestimated in rural populations.

Higher Prevalence Uncovered by Rheumatic Heart Disease Screening

Researchers conducted a study among 576 asymptomatic students aged 10 to 20 years. Using multimodal physiological data, they found a prevalence of 32.5 per 1000 population. This figure is notably higher than earlier multicenter estimates. Specifically, echocardiography identified 19 cases of RHD, divided between borderline and definite diagnoses. Furthermore, the data showed that mitral regurgitation was the predominant lesion, appearing in over 84% of cases. Consequently, these results emphasize that traditional clinical auscultation may no longer be sufficient for early detection.

Clinical Markers and Diagnostic Tools

Beyond ultrasound, the study explored electrocardiogram and phonocardiogram findings. For instance, prolonged PR intervals were observed in approximately 10.5% of the RHD-positive group. Phonocardiogram analysis detected murmurs in about half of the patients who actually had mitral regurgitation. However, nearly half of those with confirmed disease had subclinical findings, meaning they presented no audible murmur. Therefore, portable echocardiography should be prioritized as the gold standard in resource-limited settings. Moreover, identifying these silent cases allows for early intervention with secondary prophylaxis.

Improving Early Detection Strategies

Because RHD disproportionately affects vulnerable populations, mass screening programs are vital. Early detection via Rheumatic Heart Disease screening enables the administration of monthly penicillin injections. This simple treatment prevents recurrent Group A Streptococcus infections and potentially reverses early valvular changes. Although female children showed a slightly higher incidence in this cohort, the difference was not statistically significant. Thus, healthcare providers must screen all at-risk children in endemic regions to reduce the long-term impact of this preventable disease.

Frequently Asked Questions

What is the benefit of subclinical Rheumatic Heart Disease screening?

Screening identifies valvular damage before symptoms occur. This allows clinicians to start secondary penicillin prophylaxis, which can prevent disease progression and reduce the risk of heart failure or stroke in adulthood.

Is echocardiography necessary if no heart murmur is heard?

Yes. Many early-stage RHD cases are subclinical, meaning no murmur is audible through a stethoscope. Echocardiography is far more sensitive and can detect the disease even in children who appear perfectly healthy.

Can early-stage Rheumatic Heart Disease be reversed?

With consistent secondary prophylaxis and the prevention of new Group A Streptococcus infections, some early borderline or mild lesions may stabilize or even regress over time.

Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Chuma AT et al. Prevalence of Early Rheumatic Heart Disease Among Asymptomatic Students in Underserved Communities in Ethiopia: Cross-Sectional Observational Study. JMIR Public Health Surveill. 2026 Apr 17. doi: 10.2196/87039. PMID: 41996692.

Saxena A et al. Echocardiographic prevalence of rheumatic heart disease in Indian school children using World Heart Federation criteria – A multi site extension of RHEUMATIC study (the e-RHEUMATIC study). Indian Heart J. 2026;77(6).

World Heart Federation. 2012 WHF Criteria for Echocardiographic Diagnosis of Rheumatic Heart Disease. Nature Reviews Cardiology.